JP2020508339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508339A5 JP2020508339A5 JP2019546291A JP2019546291A JP2020508339A5 JP 2020508339 A5 JP2020508339 A5 JP 2020508339A5 JP 2019546291 A JP2019546291 A JP 2019546291A JP 2019546291 A JP2019546291 A JP 2019546291A JP 2020508339 A5 JP2020508339 A5 JP 2020508339A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- dosage form
- diuretic
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2017/054489 | 2017-02-27 | ||
| EP2017054489 | 2017-02-27 | ||
| EP2017061487 | 2017-05-12 | ||
| EPPCT/EP2017/061487 | 2017-05-12 | ||
| PCT/EP2017/078371 WO2018153513A1 (en) | 2017-02-27 | 2017-11-06 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508339A JP2020508339A (ja) | 2020-03-19 |
| JP2020508339A5 true JP2020508339A5 (enExample) | 2020-12-17 |
| JP7223701B2 JP7223701B2 (ja) | 2023-02-16 |
Family
ID=60268369
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546291A Active JP7223701B2 (ja) | 2017-02-27 | 2017-11-06 | ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤 |
| JP2019546286A Pending JP2020508338A (ja) | 2017-02-27 | 2018-02-26 | ４−ピリミジンスルファミド誘導体の結晶形 |
| JP2022201112A Active JP7520951B2 (ja) | 2017-02-27 | 2022-12-16 | ４－ピリミジンスルファミド誘導体の結晶形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546286A Pending JP2020508338A (ja) | 2017-02-27 | 2018-02-26 | ４−ピリミジンスルファミド誘導体の結晶形 |
| JP2022201112A Active JP7520951B2 (ja) | 2017-02-27 | 2022-12-16 | ４－ピリミジンスルファミド誘導体の結晶形 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US11174247B2 (enExample) |
| EP (3) | EP3658140B1 (enExample) |
| JP (3) | JP7223701B2 (enExample) |
| KR (3) | KR102568472B1 (enExample) |
| CN (3) | CN110325186A (enExample) |
| AU (2) | AU2017400276B2 (enExample) |
| BR (2) | BR112019017658A2 (enExample) |
| CA (2) | CA3053991A1 (enExample) |
| CL (3) | CL2019002464A1 (enExample) |
| DK (2) | DK3658140T3 (enExample) |
| ES (2) | ES3038007T3 (enExample) |
| FI (2) | FI3658140T3 (enExample) |
| HR (2) | HRP20250921T1 (enExample) |
| HU (2) | HUE072288T2 (enExample) |
| IL (4) | IL315563A (enExample) |
| LT (2) | LT3658140T (enExample) |
| MA (2) | MA49664A (enExample) |
| MX (3) | MX392313B (enExample) |
| MY (2) | MY199557A (enExample) |
| PH (2) | PH12019501937A1 (enExample) |
| PL (2) | PL3658140T3 (enExample) |
| PT (2) | PT3658140T (enExample) |
| RS (2) | RS67082B1 (enExample) |
| SG (3) | SG11201907435PA (enExample) |
| SI (2) | SI3658140T1 (enExample) |
| TW (2) | TWI786089B (enExample) |
| UA (1) | UA126122C2 (enExample) |
| WO (2) | WO2018153513A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2958110A1 (en) * | 2014-08-14 | 2016-02-18 | Vivus, Inc. | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist |
| EP3658140B1 (en) | 2017-02-27 | 2025-05-21 | Idorsia Pharmaceuticals Ltd | Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension |
| MY210547A (en) * | 2017-11-30 | 2025-09-30 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| JP7312262B2 (ja) | 2018-09-28 | 2023-07-20 | フロー メディカル コーポレイション | カテーテル装置 |
| SMT202400274T1 (it) * | 2018-12-21 | 2024-09-16 | Actelion Pharmaceuticals Ltd | Macitentan per il trattamento di ipertensione arteriosa polmonare |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
| CN112679441A (zh) * | 2019-10-18 | 2021-04-20 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的晶型、制备方法及其用途 |
| CN114630668B (zh) * | 2019-11-07 | 2024-02-27 | 苏州科睿思制药有限公司 | 一种Aprocitentan晶型及其制备方法和用途 |
| WO2021237004A1 (en) | 2020-05-21 | 2021-11-25 | Teva Pharmaceuticals International Gmbh | Solid state forms of aprocitentan and process for preparation thereof |
| CR20230083A (es) | 2020-07-10 | 2023-05-16 | Astrazeneca Ab | Combinación de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal crónica |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| WO2023111797A1 (en) * | 2021-12-17 | 2023-06-22 | Janssen Biotech, Inc. | Pyrimidine sulfamide derivatives and process for manufacturing them |
| JP2025519101A (ja) | 2022-05-22 | 2025-06-24 | イドルシア・ファーマシューティカルズ・リミテッド | 高血圧の治療のための４－ピリミジンスルファミド誘導体の使用 |
| AU2023275935A1 (en) | 2022-05-25 | 2025-01-09 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| WO2024140425A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州科睿思制药有限公司 | 一种阿普昔腾坦晶型及其制备方法和用途 |
| KR20250152723A (ko) | 2024-04-16 | 2025-10-24 | 경북대학교 산학협력단 | 신규한 피리미딘 유도체 화합물 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US569116A (en) | 1896-10-06 | Washlngtorf | ||
| ES2154277T3 (es) * | 1993-07-15 | 2001-04-01 | Hoffmann La Roche | Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina. |
| WO2002053557A1 (en) | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| AU2007217100A1 (en) | 2006-02-17 | 2007-08-30 | Gilead Colorado, Inc. | Antihypertensive therapy |
| US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
| AR061627A1 (es) | 2006-06-27 | 2008-09-10 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas |
| MX2010001837A (es) * | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| EP2545920A1 (en) * | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| DK3222277T3 (da) | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| CN102614189B (zh) * | 2012-04-17 | 2014-10-22 | 北京哈三联科技股份有限公司 | 含缬沙坦、氨氯地平和氢氯噻嗪的微丸药物组合 |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| CN107106522A (zh) | 2014-11-07 | 2017-08-29 | 艾伯维公司 | 使用液体潴留的预测因子治疗ckd的方法 |
| WO2017185142A1 (en) | 2016-04-29 | 2017-11-02 | Adelaide Research & Innovation Pty Ltd | Method for preventing and/or treating atrial fibrillation |
| EP3658140B1 (en) | 2017-02-27 | 2025-05-21 | Idorsia Pharmaceuticals Ltd | Combinations of aprocitentan with further active ingredients for the treatment of resistant hypertension |
| MY210547A (en) | 2017-11-30 | 2025-09-30 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| SMT202400274T1 (it) * | 2018-12-21 | 2024-09-16 | Actelion Pharmaceuticals Ltd | Macitentan per il trattamento di ipertensione arteriosa polmonare |
-
2017
- 2017-11-06 EP EP17794712.4A patent/EP3658140B1/en active Active
- 2017-11-06 BR BR112019017658-6A patent/BR112019017658A2/pt not_active Application Discontinuation
- 2017-11-06 FI FIEP17794712.4T patent/FI3658140T3/fi active
- 2017-11-06 SG SG11201907435PA patent/SG11201907435PA/en unknown
- 2017-11-06 WO PCT/EP2017/078371 patent/WO2018153513A1/en not_active Ceased
- 2017-11-06 DK DK17794712.4T patent/DK3658140T3/da active
- 2017-11-06 MY MYPI2019004938A patent/MY199557A/en unknown
- 2017-11-06 RS RS20250776A patent/RS67082B1/sr unknown
- 2017-11-06 PT PT177947124T patent/PT3658140T/pt unknown
- 2017-11-06 LT LTEPPCT/EP2017/078371T patent/LT3658140T/lt unknown
- 2017-11-06 PL PL17794712.4T patent/PL3658140T3/pl unknown
- 2017-11-06 KR KR1020197028199A patent/KR102568472B1/ko active Active
- 2017-11-06 HU HUE17794712A patent/HUE072288T2/hu unknown
- 2017-11-06 JP JP2019546291A patent/JP7223701B2/ja active Active
- 2017-11-06 UA UAA201909965A patent/UA126122C2/uk unknown
- 2017-11-06 HR HRP20250921TT patent/HRP20250921T1/hr unknown
- 2017-11-06 SI SI201731613T patent/SI3658140T1/sl unknown
- 2017-11-06 MA MA049664A patent/MA49664A/fr unknown
- 2017-11-06 IL IL315563A patent/IL315563A/en unknown
- 2017-11-06 CA CA3053991A patent/CA3053991A1/en active Pending
- 2017-11-06 CN CN201780087445.XA patent/CN110325186A/zh active Pending
- 2017-11-06 ES ES17794712T patent/ES3038007T3/es active Active
- 2017-11-06 IL IL268850A patent/IL268850B2/en unknown
- 2017-11-06 MX MX2019010222A patent/MX392313B/es unknown
- 2017-11-06 KR KR1020237016438A patent/KR102700778B1/ko active Active
- 2017-11-06 AU AU2017400276A patent/AU2017400276B2/en active Active
- 2017-11-06 US US16/489,227 patent/US11174247B2/en active Active
-
2018
- 2018-02-26 TW TW107106403A patent/TWI786089B/zh active
- 2018-02-26 RS RS20241269A patent/RS66200B1/sr unknown
- 2018-02-26 CN CN202311718027.XA patent/CN117946011A/zh active Pending
- 2018-02-26 SI SI201831162T patent/SI4014976T1/sl unknown
- 2018-02-26 LT LTEP21202979.7T patent/LT4014976T/lt unknown
- 2018-02-26 WO PCT/EP2018/054627 patent/WO2018154101A1/en not_active Ceased
- 2018-02-26 MA MA047596A patent/MA47596A/fr unknown
- 2018-02-26 SG SG10202111695RA patent/SG10202111695RA/en unknown
- 2018-02-26 CN CN201880014146.8A patent/CN110381948A/zh active Pending
- 2018-02-26 DK DK21202979.7T patent/DK4014976T3/da active
- 2018-02-26 FI FIEP21202979.7T patent/FI4014976T3/fi active
- 2018-02-26 IL IL297993A patent/IL297993B2/en unknown
- 2018-02-26 HR HRP20241461TT patent/HRP20241461T1/hr unknown
- 2018-02-26 HU HUE21202979A patent/HUE069231T2/hu unknown
- 2018-02-26 EP EP21202979.7A patent/EP4014976B1/en active Active
- 2018-02-26 MX MX2019010221A patent/MX2019010221A/es unknown
- 2018-02-26 PL PL21202979.7T patent/PL4014976T3/pl unknown
- 2018-02-26 KR KR1020197028200A patent/KR102577375B1/ko active Active
- 2018-02-26 ES ES21202979T patent/ES3006308T3/es active Active
- 2018-02-26 EP EP18708945.3A patent/EP3585391A1/en not_active Withdrawn
- 2018-02-26 US US16/489,194 patent/US10919881B2/en active Active
- 2018-02-26 PT PT212029797T patent/PT4014976T/pt unknown
- 2018-02-26 TW TW111142832A patent/TWI854353B/zh active
- 2018-02-26 MY MYPI2019004939A patent/MY208610A/en unknown
- 2018-02-26 SG SG11201907604UA patent/SG11201907604UA/en unknown
- 2018-02-26 CA CA3053994A patent/CA3053994A1/en active Pending
- 2018-02-26 JP JP2019546286A patent/JP2020508338A/ja active Pending
- 2018-02-26 AU AU2018225309A patent/AU2018225309B2/en active Active
- 2018-02-26 BR BR112019017644-6A patent/BR112019017644A2/pt not_active Application Discontinuation
-
2019
- 2019-08-22 PH PH12019501937A patent/PH12019501937A1/en unknown
- 2019-08-22 PH PH12019501938A patent/PH12019501938A1/en unknown
- 2019-08-22 IL IL26885219A patent/IL268852A/en unknown
- 2019-08-27 CL CL2019002464A patent/CL2019002464A1/es unknown
- 2019-08-27 MX MX2021007184A patent/MX2021007184A/es unknown
- 2019-08-27 CL CL2019002470A patent/CL2019002470A1/es unknown
-
2020
- 2020-06-30 CL CL2020001762A patent/CL2020001762A1/es unknown
-
2021
- 2021-01-12 US US17/146,801 patent/US11680058B2/en active Active
- 2021-09-10 US US17/472,349 patent/US11787782B2/en active Active
-
2022
- 2022-12-16 JP JP2022201112A patent/JP7520951B2/ja active Active
-
2023
- 2023-05-17 US US18/319,402 patent/US12297189B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| JP2021504423A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| JP2022180461A5 (enExample) | ||
| IL274943B1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| JP2015526458A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2010518122A5 (enExample) | ||
| CN101450211A (zh) | 复方降压制剂 | |
| BRPI0716302A2 (pt) | composiÇço farmacÊutica oral de liberaÇço atrasda por tempo de intervalo e mÉtodo para preparar um composiÇço farmacÊutica oral de liberaÇço atrasada por tempo de intervalo | |
| JP2020169187A (ja) | 僧帽弁疾患による無症候性心不全の患者の心臓サイズの減少及び／又は臨床的症候の発生の遅延のためのピモベンダンの使用 | |
| JP2019536816A5 (enExample) | ||
| JP2019533660A5 (enExample) | ||
| JP2014139255A5 (enExample) | ||
| CN113230411B (zh) | 一种阿利沙坦酯或其盐与钙离子通道拮抗剂的复方药物组合物 | |
| JP2008524136A5 (enExample) | ||
| JP2008533127A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP6509729B2 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| JP2006524699A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| CN113289023B (zh) | 一种阿利沙坦酯或其盐与利尿剂的药物组合物 | |
| US7625940B2 (en) | Method of treating hypertension with a very low dose of chlorthalidone | |
| JP2015515971A5 (enExample) | ||
| JP2024521354A5 (ja) | 多剤混合薬又は医薬組成物 |